Program Committee
Say “hello” to the ISPOR Asia Pacific Summit 2026 Program Committee! ISPOR is excited to work with an amazing group of talented and passionate members dedicated to curating an impactful program. It’s through their collaboration with ISPOR that we can deliver a meaningful experience to our attendees.
Co-Chairs
Vivian Lee, PharmD
Associate Professor, The Chinese University of Hong Kong, Hong Kong, China
Daniel Ng, MBA, MPH, PharmD
HEOR, Astellas Pharma, Singapore, Singapore
Members
Nathorn Chaiyakunapruk, PharmD, PhD
Professor and Graduate Program Director, Department of Pharmacotherapy, University of Utah, College of Pharmacy, Salt Lake City, Utah, USA
Sarah Chan, MBA, MPH
Director, Market Access, Novo Nordisk, Singapore, Singapore
YingYao Chen, MD, PhD
Professor of HTA and Vice Dean of Fudan University School of Public Health, Fudan University, Shanghai, China
Kevin Huang
Founder and CEO, Chinese Organization for Rare Diseases (CORD), Beijing, China
Shankar Prinja, MD, MSc
Professor of Health Economics, Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Surasak Saokaew, PharmD, PhD
Associate Professor and Dean, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
Christian Suharlim, MD, MPH
Global Health Economics and HTA Lead, Specialty Diagnostics, Thermo Fisher Scientific, Waltham, Massachusetts, USA
Eri Tajima, MSc
Head of Office Japan, Country Lead, Flatiron Health, Japan, Tokyo, Japan
Haijun Tian, PhD
Associate Vice President, Real World Evidence Strategy, Eli Lilly and Company, Chatham, New Jersey, USA
Jo Watson, MPH
Deputy Chair, Govt HTA Committee, Pharmaceutical Benefits Advisory Committee (PBAC), Canberra, Australian Capital Territory, Australia
Min Yang, MD, PhD
Managing Principal, Analysis Group, Boston, Massachusetts, USA